Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab is a novel glycoengineered, type-II anti-CD20 monoclonal antibody that was recently developed to treat follicular lymphoma (FL), the most prevalent subtype of indolent B-cell lymphoma.
|
31848991 |
2020 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this trial is a further reduction of the radiation dose in patients with nodal early-stage FL showing a good response to a combination of LDRT and anti-CD20 immunotherapy and a comparison with the currently published MIR trial.
|
31470902 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined by <i>in vivo</i> experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice.
|
31475004 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated front-line follicular lymphoma.
|
30866056 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monotherapy with the anti-CD20 monoclonal antibody rituximab can induce complete responses (CR) in patients with follicular lymphoma (FL).
|
31572357 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
This has been driven by an improved understanding of the pathobiology of FL and the development of therapeutic anti-CD20 antibodies.
|
31538821 |
2019 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a 3D co-culture assay (MALC), γδ T cells mediate both direct and indirect (ADCC in the presence of anti-CD20 mAbs) cytolytic activity against FL cell aggregates.
|
30723586 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of a chimeric anti-CD20 monoclonal antibody, rituximab, for the treatment of follicular lymphoma (FL) has dramatically improved the prognosis of this disease.
|
30715424 |
2019 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment.
|
30309758 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor cells in the regions with follicular structure showed positivity for CD20 and BCL2 consistent with an FL grade 3a diagnosis.
|
30255584 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first line treatment for symptomatic FL is chemo-immunotherapy followed by two years maintenance therapy with anti-CD20 monoclonal antibodies.
|
29972084 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the introduction of the anti-CD20 antibody rituximab, the outcome of patients with follicular lymphoma (FL) has greatly improved over the last two decades.
|
29206891 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma (FL).
|
29976619 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
In randomised clinical trials, the type II anti-CD20 antibody obinutuzumab has been shown to be more effective than rituximab for therapy of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
|
30042825 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment approach.
|
29934061 |
2018 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sections of axillary lymph node demonstrated potentially 2 clonal processes, PTCL with aberrant CD20 expression and follicular lymphoma.
|
29217426 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children's Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment with maintenance rituximab or no-maintenance rituximab.
|
28659916 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients aged >18 years with CD20+ relapsed/refractory chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) were enrolled from four centres in China.
|
28072473 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the role of three SNP-associated complement-regulatory proteins (CFH, CFHR1, and CFHR3) in clinical response to anti-CD20 mAb, we studied two cohorts of patients treated with anti-CD20 mAb.<b>Experimental Design:</b> Cohorts included the Iowa/Mayo Lymphoma SPORE observational cohort of subjects with a new diagnosis of follicular lymphoma treated with rituximab and the GAUSS prospective randomized trial cohort of follicular lymphoma subjects randomized to receive single-agent rituximab or obinutuzumab.
|
27528699 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab (OBZ) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody (mAb), recently approved in chronic lymphocytic leukemia (CLL; B-cell CLL) and follicular lymphoma (FL).
|
28584136 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
They were positive for CD20 and BCL-2, and had low-to-intermediate Ki-67 proliferation index (10%-40%) except in the parotid DLBCL with FL (70%).
|
28038709 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most previously untreated patients with CD20+ DLBCL or FL preferred s.c. to i.v. rituximab administration.
|
28031173 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab.
|
28435325 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
|
24717109 |
2015 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
AME-133v showed encouraging results as an anti-CD20 therapy in heavily pretreated FL patients with the less favorable FcγRIIIa F-carrier genotype.
|
22223529 |
2012 |